They also raise a possibility that pan-HDAC inhibitors (e.g., CS055 and SAHA) might be superior to HDAC isoform-selective inhibitors (e.g., romidepsin) in potentiation of ABT-199 lethality toward AML cells. Here, HDAC9 is linked to acute myeloid leukemia.